DUEXIS Drug Patent Profile

Which patents cover Duexis, and when can generic versions of Duexis launch?

Duexis is a drug marketed by Horizon and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

DrugPatentWatch^® Generic Entry Outlook for Duexis

There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for DUEXIS

International Patents:	25
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	154
Drug Prices:	Drug price information for DUEXIS
Drug Sales Revenues:	Drug sales revenues for DUEXIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DUEXIS
What excipients (inactive ingredients) are in DUEXIS?	DUEXIS excipients list
DailyMed Link:	DUEXIS at DailyMed

See drug prices for DUEXIS

See drug sales revenues for DUEXIS

Recent Clinical Trials for DUEXIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 4
Pediatric Rheumatology Collaborative Study Group	Phase 4

See all DUEXIS clinical trials

Paragraph IV (Patent) Challenges for DUEXIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUEXIS	Tablets	famotidine; ibuprofen	800 mg/26.6 mg	022519	1	2011-12-06

US Patents and Regulatory Information for DUEXIS

DUEXIS is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No			Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No			Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No			Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No			Y

International Patents for DUEXIS

When does loss-of-exclusivity occur for DUEXIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DUEXIS around the world.

Country	Patent Number	Title	Estimated Expiration
China	101516368	Methods and medicaments for administration of ibuprofen
Spain	2380747
Israel	188732	שימוש באיבופרופין ופאמוטידין להכנת תרופות (Use of ibuprofen and famotidine in the preparation of medicaments)
China	101516368
Japan	2009543885

DUEXIS: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is DUEXIS in the market?

DUEXIS is a fixed-dose combination product: ibuprofen 800 mg + famotidine 26.6 mg in one tablet, targeting osteoarthritis and other chronic pain indications while reducing upper gastrointestinal (UGI) injury risk via the H2 blocker component. It is marketed by Sunovion Pharmaceuticals, Inc. and has a long-term commercial footprint in US prescription channels.

Key product construction that shapes demand

• Therapeutic value proposition: combines an NSAID with gastroprotection (famotidine) in a single dose.
• Differentiation axis: reduces reliance on separate gastroprotective prescribing compared with a generic NSAID plus separate H2 blocker.
• Switchability: the drug is still exposed to substitution because its active NSAID (ibuprofen) is broadly generic and because H2 blockers are widely generic.

---

What drove initial adoption and early uptake?

DUEXIS adoption followed a classic specialty-to-managed-care rollout pattern for combo “risk-management” NSAID therapy.

1. Clinically targeted prescribing: DUEXIS is positioned for patients who need ongoing NSAID therapy and who carry GI-risk considerations where prescribers want a standardized approach rather than ad hoc co-therapy.
2. Economic fit in formularies: managed care adoption depended on whether payers viewed the combo as a cost-effective alternative versus:
   • generic ibuprofen alone (lowest drug cost but higher perceived GI risk), or
   • generic ibuprofen plus PPI/H2 blocker (higher complexity and often higher total pharmacy cost).
3. Branding around GI risk: marketing emphasized UGI protection logic to justify price above generic ibuprofen.

The product’s long-run demand is therefore structurally tied to two payer levers:

• placement in preferred or non-preferred NSAID tiers, and
• restrictions or step edits tied to GI-risk language, age, or concurrent meds.

---

How do market dynamics shape DUEXIS demand today?

DUEXIS competes in the US NSAID market where baseline demand is large but payer scrutiny is intense, especially for brands where one or more actives are generic.

Competitive landscape and substitution pressure

DUEXIS sits in a crowded substitution environment:

• Generic ibuprofen and other NSAIDs capture price-sensitive patients.
• Combination gastroprotection strategies compete, including:
  • OTC or generic H2 blockers used alongside NSAIDs,
  • PPIs (often considered stronger UGI protection, depending on payer and patient profile),
  • other fixed-dose or branded NSAID-with-gastroprotection options where applicable.

Because the NSAID component is generic-available, the main defense is formulary placement and perceived regimen simplicity (single tablet), not molecular uniqueness.

Payer behavior and utilization steering

In most managed care environments, branded NSAID use is shaped by:

• prior authorization criteria (GI history, age, failure/intolerance to step therapy),
• quantity and days-supply caps for chronic dosing,
• preferred NSAID step lists that push patients to lower-cost generics when clinically acceptable.

DUEXIS’s utilization trajectory is therefore usually “resistance-driven”: it can persist and grow modestly in favorable plan cohorts but rarely expands at the expense of broad generic displacement without payer or clinical triggers.

Class risks that affect sustained use

NSAIDs are high-volume but also high-liability drugs for GI bleeding and cardiovascular risk. That risk reality influences both prescriber behavior and payer coverage:

• payers often restrict NSAIDs for patients at elevated risk for complications,
• prescribers may shift toward agents with other risk profiles depending on patient comorbidities.

DUEXIS’s H2-based gastroprotection can help on UGI risk, but it does not fully remove the broader NSAID class risk set.

---

What is the regulatory and commercial status that matters for financial trajectory?

DUEXIS’s US commercial continuity depends on patent position, exclusivity, and the strength of legal protections around the fixed-dose combination and its manufacturing/claims.

The product remains active as an FDA-approved prescription medicine and is available for US distribution under its brand labeling and REMS status (if any), but the major revenue driver for “steady state” performance is typically formulary access rather than regulatory milestones after initial commercialization.

---

How has financial trajectory typically looked for DUEXIS in the brand lifecycle?

For combination NSAID brands with generic NSAID actives, the common financial shape over time is:

• Early ramp: adoption in targeted prescriber segments and favorable formularies.
• Mid-cycle stability: continued niche use where payers allow brand access for GI-risk or simplicity arguments.
• Late-cycle plateau: slow decline or flat sales after additional payer pressure, step edits, and generic dominance in many plans.

For DUEXIS specifically, this lifecycle pattern is consistent with:

• commoditization pressure from generic ibuprofen,
• ongoing payer substitution behavior,
• patient steering toward lower-cost regimens unless coverage remains favorable.

---

What does the market imply about revenue levers and cost structure?

DUEXIS’s economics hinge on how payers and channels treat:

1. Net price vs. list price: brands with generics underneath typically face heavy rebates and access rebates. Net revenue depends on managed care uptake and discounting intensity.
2. Distribution and channel mix: pharmacy benefit plan coverage and mail order share affect utilization consistency.
3. Dosing regimen persistence: as a chronic pain medicine, it can maintain volume if patients stay on a covered regimen. If step therapy increases, persistence drops and switching increases.
4. Formulary “stickiness”: fixed-dose combo convenience can increase stickiness in the subset of plans that keep it available without onerous restrictions.

---

What is the near-term outlook from a dynamics standpoint?

The forward path for DUEXIS depends less on clinical breakthroughs and more on:

• how widely plans maintain the combo as a covered option for GI-risk populations,
• whether payers increasingly require failure on generic NSAID plus separate gastroprotection first,
• whether broader NSAID class prescribing trends reduce overall NSAID utilization for safety reasons.

In this structure, the highest-impact determinants of financial trajectory are payer actions, not new product launches.

---

Competitive positioning summary

Dimension	DUEXIS position	Main impact on sales
Core therapy	NSAID + H2 blocker in one tablet	Differentiation is regimen-level, not active ingredient novelty
Generic substitution	Ibuprofen is widely generic	High payer-driven switching pressure
Payer controls	Often tiering and step/PA rules in managed care	Net sales sensitive to formulary access
Patient persistence	Chronic use potential	Stability when coverage remains consistent
Safety-related prescribing	NSAID class risk influences utilization	Can cap growth even with gastroprotection

---

Key takeaways

• DUEXIS competes in a large but substitution-heavy NSAID market where the NSAID active (ibuprofen) is generic, so sustained performance depends on formulary access and managed care steering rather than molecular exclusivity.
• The product’s financial trajectory follows a mature branded lifecycle shape: early niche adoption, then mid-cycle stability, then plateau under payer pressure.
• The dominant revenue levers are net price (rebates and access discounts) and utilization persistence in cohorts where plans keep DUEXIS covered for GI-risk logic.

---

FAQs

1. Is DUEXIS protected by patents that prevent generic entry?
   DUEXIS has a fixed-dose combination and associated IP protections historically tied to combo-specific claims and exclusivity, but its market performance is still heavily shaped by generic substitution risk of ibuprofen.

2. What drives DUEXIS differentiation versus generic NSAIDs?
   The differentiation is regimen convenience: a single-tablet NSAID plus H2 blocker rather than generic NSAID alone, which can reduce co-therapy prescribing friction for GI-risk patients.

3. How do payers typically evaluate DUEXIS?
   Payers commonly use formulary tiering and step therapy/prior authorization focusing on whether patients meet GI-risk criteria where the combination is clinically justified.

4. What utilization trend should investors expect in mature NSAID brands?
   In mature stages with broad generic availability, utilization usually becomes range-bound and tied to payer coverage rather than rapid share expansion.

5. What is the biggest business risk for DUEXIS?
   Escalation of payer restriction intensity (step edits, PA requirements, narrower criteria) that increases switching to lower-cost NSAID regimens.

---

References (APA)

[1] FDA. (n.d.). Drug products (DUEXIS) information and labeling. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/